Friday, 22 Jun 2018

You are here

The RheumNow Week in Review – Baricitinib Splash (6.7.18)

Dr. Jack Cush discusses the past week's news and journal articles featured on RheumNow.com - including reports on advance practice clinicians, baricitinib, gout, disease activity, hypomagnesemia and upadacitinib.

  1. Literature review finds 4 studies showing Mirtazpine use in fibromyalgia resulted in significant improvements in pain, sleep, and quality of life. https://t.co/66U7ZRYhW3 
  2. Abbvie announced resultes of its SELECT EARLY study of MTX vs upadacitinib monotherapy in MTX-naïve RA pts. Wk 24 ACR 20 was MTX=59% and UPA 78-79%; ACR70 MTX=16% vs UPA=44-50%. UPA had less VTE than MTX. https://t.co/xKBQQ96kVX
  3. CORRONA registry study >45k pts shows betw 2002-2013 biologic use in RA & PsA rose to 62% & 52%, with significantly improved measures (CDAI, HAQ), but 35% & 25% of RA & PsA continued w/ moderate/high disease activity. https://t.co/4pO3kTvTre
  4. JBMR reports a single center study showing that among 53 severe osteoporosis patients treated w/ teriparitide, hypomagnesemia was seen in 36% - risk factors include older age and lower baseline Mg levels. Consider monitoring Mg https://t.co/NUKwHjWkq8 
  5. Study of preclinical samples from 83 subsequent RA pts shows that double positivity (RF+ ACPA+) is associated with higher levels of proinflammatory cytokines and more rapid progression to develop #RA. https://t.co/b7zwDHAqkd
  6. FDA approves the combo drug Consensi (amlodipine and celecoxib) for Treatment of Hypertension and Osteoarthritis Pain - is this brilliant or an expensive brand of stupid? https://t.co/RZO0wOl6T8
  7. Between 2008-2016, nurse practitioner (NP) utilization in ng NP presence in primary care practices rose in rural (17.6% to 25.2%) and nonrural (15.9% to 23%) practices and was highest in states with full scope-of-practice laws for NPs. https://t.co/MG12S1zZry 
  8. Advance Practice Clinicians Proliferating in Specialty Practices 
  9. SPAR Predicts ILD Progression in Systemic Sclerosis  
  10. Sons of Gout Study 
  11. Long Term Remission in SLE is Possible?  
  12. FDA Approves Baricitinib 2 mg for Rheumatoid Arthritis   

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review – EULAR18 Epilogue (6.22.18)

Dr. Jack Cush reviews EULAR 2018 and the past week's news and reports from RheumNow.com, including DMARDs in OA, the price of Penicillamine, Infections when ANCA+, CV outcomes in gout, NSAIDs in Pregnancy and Seropostive vs. Seronegative Outcomes.

CDC Obesity Prevalence Higher in the Rural USA

MMWR reports that approximately 46 million persons (14%) in the United States live in nonmetropolitan counties, where there is a higher prevalence of obesity-associated chronic diseases such as diabetes, coronary heart disease, and arthritis. (Citation source: http://bit.ly/2lj5yql)

EULAR 2018 - Podcast from Day 4

This EULAR 2018 Podcast is a compilation of audio clips from EULAR in Amsterdam.

Click HERE to listen.

You can also listen on iTunes, Soundcloud or Stitcher.

EULAR 2018 - Podcast from Day 3

This EULAR 2018 Podcast is a compilation of audio clips from EULAR in Amsterdam.

Click HERE to listen.

You can also listen on iTunes, Soundcloud or Stitcher. 

The RheumNow Week in Review – EULAR18 Abbreviated (6.15.18)

We're crazy busy at EULAR all week.  Instead of this review, we recommend that you tune into our multiple podcasts from experts and faculty attending EULAR 2018 in Amsterdam.  You can find these on iTunes, SoundCloud or Stitcher.

Tune in next week for the EULAR week in review!